+

WO2002007780A3 - Procedes d'identification de cibles therapeutiques destinees a traiter des maladies infectieuses - Google Patents

Procedes d'identification de cibles therapeutiques destinees a traiter des maladies infectieuses Download PDF

Info

Publication number
WO2002007780A3
WO2002007780A3 PCT/US2001/023095 US0123095W WO0207780A3 WO 2002007780 A3 WO2002007780 A3 WO 2002007780A3 US 0123095 W US0123095 W US 0123095W WO 0207780 A3 WO0207780 A3 WO 0207780A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
therapeutic targets
identifying therapeutic
enzymes
compounds
Prior art date
Application number
PCT/US2001/023095
Other languages
English (en)
Other versions
WO2002007780A2 (fr
Inventor
Michael H Shepard
David B Lackey
Brian E Cathers
Maria V Sergeeva
Original Assignee
Newbiotics Inc
Michael H Shepard
David B Lackey
Brian E Cathers
Maria V Sergeeva
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newbiotics Inc, Michael H Shepard, David B Lackey, Brian E Cathers, Maria V Sergeeva filed Critical Newbiotics Inc
Priority to AU2001277093A priority Critical patent/AU2001277093A1/en
Publication of WO2002007780A2 publication Critical patent/WO2002007780A2/fr
Publication of WO2002007780A3 publication Critical patent/WO2002007780A3/fr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/556—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells enzyme catalyzed therapeutic agent [ECTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Medical Informatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Veterinary Medicine (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Zoology (AREA)
  • Nanotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des procédés et des systèmes d'identification d'enzymes qui agissent en tant qu'activateurs thérapeutiques catalysés par des enzymes et des enzymes identifiées au moyen de ces procédés. L'invention concerne également des composés activés par ces enzymes, ainsi que des compositions contenant ces composés.
PCT/US2001/023095 2000-07-20 2001-07-20 Procedes d'identification de cibles therapeutiques destinees a traiter des maladies infectieuses WO2002007780A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001277093A AU2001277093A1 (en) 2000-07-20 2001-07-20 Methods for identifying therapeutic targets

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US21959800P 2000-07-20 2000-07-20
US60/219,598 2000-07-20
US24495300P 2000-11-01 2000-11-01
US60/244,953 2000-11-01
US27672801P 2001-03-16 2001-03-16
US60/276,728 2001-03-16

Publications (2)

Publication Number Publication Date
WO2002007780A2 WO2002007780A2 (fr) 2002-01-31
WO2002007780A3 true WO2002007780A3 (fr) 2003-02-20

Family

ID=27396678

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/023095 WO2002007780A2 (fr) 2000-07-20 2001-07-20 Procedes d'identification de cibles therapeutiques destinees a traiter des maladies infectieuses

Country Status (2)

Country Link
AU (1) AU2001277093A1 (fr)
WO (1) WO2002007780A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04010230A (es) * 2002-04-18 2005-06-08 Celmed Oncology Usa Inc Profarmacos de peptido deformilasa activada.

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999008110A1 (fr) * 1997-08-08 1999-02-18 Newbiotics, Inc. Methodes et compositions pour surmonter la resistance a une therapie biologique et a une chimiotherapie
WO1999037753A1 (fr) * 1998-01-23 1999-07-29 Newbiotics, Inc. Agents therapeutiques obtenus par catalyse enzymatique
WO2001007088A2 (fr) * 1999-07-22 2001-02-01 Newbiotics, Inc. Procedes pour traiter les tumeurs resistantes aux therapies
WO2001007454A1 (fr) * 1999-07-22 2001-02-01 Newbiotics, Inc. Activation therapeutique catalysee par des enzymes
WO2001007087A2 (fr) * 1999-07-22 2001-02-01 Newbiotics, Inc. Agents therapeutiques anti-infectieux catalyses par des enzymes
WO2001064687A1 (fr) * 2000-02-28 2001-09-07 Newbiotics, Inc. Ectatm anti-infectieux
WO2001083492A1 (fr) * 2000-05-02 2001-11-08 Newbiotics, Inc. Antibiotiques de la famille des beta-lactamines ameliores

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999008110A1 (fr) * 1997-08-08 1999-02-18 Newbiotics, Inc. Methodes et compositions pour surmonter la resistance a une therapie biologique et a une chimiotherapie
WO1999037753A1 (fr) * 1998-01-23 1999-07-29 Newbiotics, Inc. Agents therapeutiques obtenus par catalyse enzymatique
WO2001007088A2 (fr) * 1999-07-22 2001-02-01 Newbiotics, Inc. Procedes pour traiter les tumeurs resistantes aux therapies
WO2001007454A1 (fr) * 1999-07-22 2001-02-01 Newbiotics, Inc. Activation therapeutique catalysee par des enzymes
WO2001007087A2 (fr) * 1999-07-22 2001-02-01 Newbiotics, Inc. Agents therapeutiques anti-infectieux catalyses par des enzymes
WO2001064687A1 (fr) * 2000-02-28 2001-09-07 Newbiotics, Inc. Ectatm anti-infectieux
WO2001083492A1 (fr) * 2000-05-02 2001-11-08 Newbiotics, Inc. Antibiotiques de la famille des beta-lactamines ameliores

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BOYER, CHRISTOPHER R. (1) ET AL: "NB1011, a novel drug that targets tumor cells overexpressing thymidilate synthase, induces p21, BAX and GADD45 and blocks G2/M cell cycle progression in MCF7TDX cells.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, (MARCH, 2001) VOL. 42, PP. 507-508. PRINT. MEETING INFO.: 92ND ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH NEW ORLEANS, LA, USA MARCH 24-28, 2001, XP002204185 *
LACKEY, D. B. ET AL: "Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase", BIOCHEMICAL PHARMACOLOGY (2001), 61(2), 179-189, XP002204184 *
LI, QING ET AL: "A novel approach to thymidylate synthase as a target for cancer chemotherapy", MOLECULAR PHARMACOLOGY (2001), 59(3), 446-452, XP002204186 *
SMYTH, TIMOTHY P. ET AL: "S-Aminosulfeniminopenicillins: Multimode. beta.- Lactamase Inhibitors and Template Structures for Penicillin-Based. beta.- Lactamase Substrates as Prodrugs", JOURNAL OF ORGANIC CHEMISTRY (1998), 63(22), 7600-7618, XP002204183 *

Also Published As

Publication number Publication date
AU2001277093A1 (en) 2002-02-05
WO2002007780A2 (fr) 2002-01-31

Similar Documents

Publication Publication Date Title
WO1999043651A3 (fr) Inhibiteurs d'enzymes phospholipases
WO1999057325A3 (fr) Melanges d'enzymes
ZA200108016B (en) Pyrazolobenzodiazephines as CDK2 inhibitors.
WO2004037159A3 (fr) Composes, compositions et methodes permettant de moduler le metabolisme des graisses
AU2002359522A1 (en) Compositions and methods of selective nucleic acid isolation
AU2001228309A1 (en) N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv
AU6895801A (en) Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv
WO2005030791A3 (fr) Inhibiteurs du canal potassique d'isoquinolinone
PL319605A1 (en) Novel benzoxazoles
WO2002000651A3 (fr) Inhibiteurs du facteur xa
WO2007026251A8 (fr) Utilisation d'inhibiteurs combines c-kit/fgfr3 pour le traitement du myelome multiple
ZA991975B (en) Enzyme inhibitors.
WO2005030129A3 (fr) Inhibiteurs des canaux potassiques a la quinoleine
WO2005030130A3 (fr) Inhibiteurs des canaux potassiques a l'isoquinoleine
ZA992448B (en) Quinoxalinones as serine protease inhibitors.
WO2001014584A3 (fr) Identification d'agents antiviraux
WO2006063055A3 (fr) Conjugues enzymatiques utilises en tant qu'agents detoxifiants
AU2002241873A1 (en) Whitening compositions containing ascomycete derived enzyme
AU2001262732A1 (en) Inhibitor for enzyme having two divalent metal ions as active centers
WO2005030792A3 (fr) Inhibiteurs du canal potassique de quinoline
AU6839300A (en) Nucleic acids which code for the enzyme activities of the spinosyn biosynthesis
WO2005123913A3 (fr) Compositions d'enzymes thermostables modifiees de façon reversible, et methodes de production et d'utilisation desdites compositions
DE60022095D1 (en) Camptothecin-beta-alanin-ester mit topoisomerase i hemmung
WO2002038106A3 (fr) Composes calcilytiques
WO2003087054A3 (fr) Methodes d'identification de composes modulant l'activite enzymatique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载